% alzhub.org library filter
% Source: https://alzhub.org/research?category=drug_development&design=trial
% 32 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{abdelhaleem2026-40435316,
  author  = {Abdel-Haleem, Alyaa M and Casavant, Ellen and Toth, Balazs and Teng, Edmond and Monteiro, Cecilia and Pandya, Nikhil J and Glock, Caspar and Hoogenraad, Casper C and others},
  title   = {{CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures}},
  journal = {Brain : a journal of neurology},
  year    = {2026},
  doi     = {10.1093/brain/awaf200},
  pmid    = {40435316},
  url     = {https://doi.org/10.1093/brain/awaf200}
}

@article{jeong2022-36038268,
  author  = {Jeong, S. Y. and Suh, C. H. and Shim, W. H. and Lim, J. S. and Lee, J. H. and Kim, S. J.},
  title   = {{Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis}},
  journal = {Neurology},
  year    = {2022},
  doi     = {10.1212/wnl.0000000000201019},
  pmid    = {36038268},
  url     = {https://doi.org/10.1212/wnl.0000000000201019}
}

@article{schauer2024-39513754,
  author  = {Schauer, Stephen P and Toth, Balazs and Lee, Julie and Honigberg, Lee A and Ramakrishnan, Vidya and Jiang, Jenny and Kollmorgen, Gwendlyn and Bayfield, Anna and others},
  title   = {{Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2024},
  doi     = {10.1002/alz.14346},
  pmid    = {39513754},
  url     = {https://doi.org/10.1002/alz.14346}
}

@article{baddeley2015-25320049,
  author  = {Baddeley, T. C. and McCaffrey, J. and Storey, J. M. and Cheung, J. K. and Melis, V. and Horsley, D. and Harrington, C. R. and Wischik, C. M.},
  title   = {{Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease}},
  journal = {The Journal of pharmacology and experimental therapeutics},
  year    = {2015},
  doi     = {10.1124/jpet.114.219352},
  pmid    = {25320049},
  url     = {https://doi.org/10.1124/jpet.114.219352}
}

@article{loomis2024-38165296,
  author  = {Loomis, S. J. and Miller, R. and Castrillo-Viguera, C. and Umans, K. and Cheng, W. and O'Gorman, J. and Hughes, R. and Budd Haeberlein, S. and others},
  title   = {{Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies}},
  journal = {Neurology},
  year    = {2024},
  doi     = {10.1212/wnl.0000000000207919},
  pmid    = {38165296},
  url     = {https://doi.org/10.1212/wnl.0000000000207919}
}

@article{cummings2022-35516416,
  author  = {Cummings, J. and Lee, G. and Nahed, P. and Kambar, M. E. Z. N. and Zhong, K. and Fonseca, J. and Taghva, K.},
  title   = {{Alzheimer's disease drug development pipeline: 2022}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2022},
  doi     = {10.1002/trc2.12295},
  pmid    = {35516416},
  url     = {https://doi.org/10.1002/trc2.12295}
}

@article{cummings2024-38659717,
  author  = {Cummings, J. and Zhou, Y. and Lee, G. and Zhong, K. and Fonseca, J. and Cheng, F.},
  title   = {{Alzheimer's disease drug development pipeline: 2024}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2024},
  doi     = {10.1002/trc2.12465},
  pmid    = {38659717},
  url     = {https://doi.org/10.1002/trc2.12465}
}

@article{ramakrishnan2024-39350369,
  author  = {Ramakrishnan, V and Bender, B and Langenhorst, J and Magnusson, M O and Dolton, M and Shim, J and Fuji, R N and Monteiro, C and others},
  title   = {{Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2024},
  doi     = {10.14283/jpad.2024.146},
  pmid    = {39350369},
  url     = {https://doi.org/10.14283/jpad.2024.146}
}

@article{cummings2021-34095440,
  author  = {Cummings, J. and Lee, G. and Zhong, K. and Fonseca, J. and Taghva, K.},
  title   = {{Alzheimer's disease drug development pipeline: 2021}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2021},
  doi     = {10.1002/trc2.12179},
  pmid    = {34095440},
  url     = {https://doi.org/10.1002/trc2.12179}
}

@article{vitek2023-36749830,
  author  = {Vitek, G. E. and Decourt, B. and Sabbagh, M. N.},
  title   = {{Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease}},
  journal = {Expert opinion on investigational drugs},
  year    = {2023},
  doi     = {10.1080/13543784.2023.2178414},
  pmid    = {36749830},
  url     = {https://doi.org/10.1080/13543784.2023.2178414}
}

@article{west2017-29181488,
  author  = {West, T. and Hu, Y. and Verghese, P. B. and Bateman, R. J. and Braunstein, J. B. and Fogelman, I. and Budur, K. and Florian, H. and others},
  title   = {{Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2017},
  doi     = {10.14283/jpad.2017.36},
  pmid    = {29181488},
  url     = {https://doi.org/10.14283/jpad.2017.36}
}

@article{nowell2023-36258018,
  author  = {Nowell, J. and Blunt, E. and Edison, P.},
  title   = {{Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease}},
  journal = {Molecular psychiatry},
  year    = {2023},
  doi     = {10.1038/s41380-022-01792-4},
  pmid    = {36258018},
  url     = {https://doi.org/10.1038/s41380-022-01792-4}
}

@article{cummings2025-39971900,
  author  = {Cummings, Jeffrey L and Zhou, Yadi and Van Stone, Alexandra and Cammann, Davis and Tonegawa-Kuji, Reina and Fonseca, Jorge and Cheng, Feixiong},
  title   = {{Drug repurposing for Alzheimer's disease and other neurodegenerative disorders}},
  journal = {Nature communications},
  year    = {2025},
  doi     = {10.1038/s41467-025-56690-4},
  pmid    = {39971900},
  url     = {https://doi.org/10.1038/s41467-025-56690-4}
}

@article{santerre2026-42962966,
  author  = {Santerre, Maryline and Shcherbik, Natalia and Sawaya, Bassel E},
  title   = {{The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration}},
  journal = {Metabolism: clinical and experimental},
  year    = {2026},
  doi     = {10.1016/j.metabol.2026.156810},
  pmid    = {42962966},
  url     = {https://doi.org/10.1016/j.metabol.2026.156810}
}

@article{tianhuikwan2020-33321511,
  author  = {Tian Hui Kwan, A. and Arfaie, S. and Therriault, J. and Rosa-Neto, P. and Gauthier, S.},
  title   = {{Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials}},
  journal = {Dementia and geriatric cognitive disorders},
  year    = {2020},
  doi     = {10.1159/000511506},
  pmid    = {33321511},
  url     = {https://doi.org/10.1159/000511506}
}

@article{zack2015-2d3045db,
  author  = {Zack, Julia and Berg, Jolene and Juan, Axel and Pannacciulli, Nicola and Allard, Martine and Gottwald, Mildred and Zhang, Heather and Shao, Yongwu and others},
  title   = {{Pharmacokinetic drug–drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus}},
  journal = {Clinical Pharmacology in Drug Development},
  year    = {2015},
  doi     = {10.1002/cpdd.174},
  url     = {https://doi.org/10.1002/cpdd.174}
}

@article{ayalon2021-33980574,
  author  = {Ayalon, G. and Lee, S. H. and Adolfsson, O. and Foo-Atkins, C. and Atwal, J. K. and Blendstrup, M. and Booler, H. and Bravo, J. and others},
  title   = {{Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease}},
  journal = {Science translational medicine},
  year    = {2021},
  doi     = {10.1126/scitranslmed.abb2639},
  pmid    = {33980574},
  url     = {https://doi.org/10.1126/scitranslmed.abb2639}
}

@article{wang2023-37730113,
  author  = {Wang, Z. J. and Li, X. R. and Chai, S. F. and Li, W. R. and Li, S. and Hou, M. and Li, J. L. and Ye, Y. C. and others},
  title   = {{Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway}},
  journal = {Neuropharmacology},
  year    = {2023},
  doi     = {10.1016/j.neuropharm.2023.109716},
  pmid    = {37730113},
  url     = {https://doi.org/10.1016/j.neuropharm.2023.109716}
}

@article{marasco2020-32840330,
  author  = {Marasco, R. A.},
  title   = {{Current and evolving treatment strategies for the Alzheimer disease continuum}},
  journal = {The American journal of managed care},
  year    = {2020},
  doi     = {10.37765/ajmc.2020.88481},
  pmid    = {32840330},
  url     = {https://doi.org/10.37765/ajmc.2020.88481}
}

@article{cummings2019-31062825,
  author  = {Cummings, J and Blennow, K and Johnson, K and Keeley, M and Bateman, R J and Molinuevo, J L and Touchon, J and Aisen, P and others},
  title   = {{Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force}},
  journal = {The journal of prevention of Alzheimer's disease},
  year    = {2019},
  doi     = {10.14283/jpad.2019.14},
  pmid    = {31062825},
  url     = {https://doi.org/10.14283/jpad.2019.14}
}

@article{giagkou2019-31007097,
  author  = {Giagkou, Nikolaos and Stamelou, Maria},
  title   = {{Emerging drugs for progressive supranuclear palsy}},
  journal = {Expert opinion on emerging drugs},
  year    = {2019},
  doi     = {10.1080/14728214.2019.1609450},
  pmid    = {31007097},
  url     = {https://doi.org/10.1080/14728214.2019.1609450}
}

@article{jiang2019-31667754,
  author  = {Jiang, Jie and Ravits, John},
  title   = {{Pathogenic Mechanisms and Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis/Frontotemporal Dementia}},
  journal = {Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics},
  year    = {2019},
  doi     = {10.1007/s13311-019-00797-2},
  pmid    = {31667754},
  url     = {https://doi.org/10.1007/s13311-019-00797-2}
}

@article{riedel2020-32091331,
  author  = {Riedel, Gernot and Klein, Jochen and Niewiadomska, Grazyna and Kondak, Constantin and Schwab, Karima and Lauer, Dilyara and Magbagbeolu, Mandy and Steczkowska, Marta and others},
  title   = {{Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model}},
  journal = {Current Alzheimer research},
  year    = {2020},
  doi     = {10.2174/1567205017666200224120926},
  pmid    = {32091331},
  url     = {https://doi.org/10.2174/1567205017666200224120926}
}

@article{athauda2016-26851597,
  author  = {Athauda, D. and Foltynie, T.},
  title   = {{The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action}},
  journal = {Drug discovery today},
  year    = {2016},
  doi     = {10.1016/j.drudis.2016.01.013},
  pmid    = {26851597},
  url     = {https://doi.org/10.1016/j.drudis.2016.01.013}
}

@article{elghanam2024-38669547,
  author  = {Elghanam, Y. and Purja, S. and Kim, E. Y.},
  title   = {{Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2024},
  doi     = {10.3233/jad-240008},
  pmid    = {38669547},
  url     = {https://doi.org/10.3233/jad-240008}
}

@article{muralidharan2022-35285968,
  author  = {Muralidharan, K. K. and Karumanchi, S. and Kowalski, K. G. and Burkett, P. and Chapel, S. and Rajagovindan, R. and Nestorov, I.},
  title   = {{A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease}},
  journal = {Journal of clinical pharmacology},
  year    = {2022},
  doi     = {10.1002/jcph.2047},
  pmid    = {35285968},
  url     = {https://doi.org/10.1002/jcph.2047}
}

@article{raja2026-d1c44bbc,
  author  = {Raja, Michelle and Patel, Khush and Krish, Pranav and Chow, Chrissy and Azam, Zaki},
  title   = {{GLP-1 Receptor Agonists Beyond Glycemic Control: Clinical Implications in Neurodegenerative Disease and Substance Use Disorders}},
  journal = {Journal of Community Hospital Internal Medicine Perspectives},
  year    = {2026},
  doi     = {10.55729/2000-9666.1651},
  url     = {https://doi.org/10.55729/2000-9666.1651}
}

@article{doherty2022-35622461,
  author  = {Doherty, T. and Gee, M. and Maruff, P. and Smith, R. and Murphy, J. and Marsh, J. and Koschalka, L. and Martinez, M. and others},
  title   = {{Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2022},
  doi     = {10.1097/wad.0000000000000508},
  pmid    = {35622461},
  url     = {https://doi.org/10.1097/wad.0000000000000508}
}

@article{tato2022-35468638,
  author  = {Tatò, M. and Perneczky, R.},
  title   = {{[Diagnosing Alzheimer's dementia - a playground for academics or a sensible clinical measure?]}},
  journal = {Deutsche medizinische Wochenschrift (1946)},
  year    = {2022},
  doi     = {10.1055/a-1769-1376},
  pmid    = {35468638},
  url     = {https://doi.org/10.1055/a-1769-1376}
}

@article{vanacore2021-34263875,
  author  = {Vanacore, N. and Blasimme, A. and Canevelli, M.},
  title   = {{[Aducanumab and Alzheimer's disease: a critical reflection.]}},
  journal = {Recenti progressi in medicina},
  year    = {2021},
  doi     = {10.1701/3638.36183},
  pmid    = {34263875},
  url     = {https://doi.org/10.1701/3638.36183}
}

@article{day2022-35197360,
  author  = {Day, G. S. and Scarmeas, N. and Dubinsky, R. and Coerver, K. and Mostacero, A. and West, B. and Wessels, SR. and Armstrong, M. J.},
  title   = {{Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus [RETIRED]: A Report of the AAN Guidelines Subcommittee}},
  journal = {Neurology},
  year    = {2022},
  doi     = {10.1212/wnl.0000000000200176},
  pmid    = {35197360},
  url     = {https://doi.org/10.1212/wnl.0000000000200176}
}

@article{sulter2026-7e0e4d07,
  author  = {Sulter, G. A.},
  title   = {{Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine}},
  journal = {Preprints.org},
  year    = {2026},
  doi     = {10.20944/preprints202607.1279.v1},
  url     = {https://doi.org/10.20944/preprints202607.1279.v1}
}